Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tisagenlecleucel reinfusion in pediatric and adolescent/young adult acute lymphoblastic leukemia with loss of B-cell aplasia
2021-001535-99Phase 2
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Primary endpoint: Establishment of B-cell aplasia within 12 months after reinfusion.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2021-001535-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001535-99.